Clinical and radiological characteristics of Mpox pneumonia in immunosuppressed HIV-infected patients: a multicenter study from China

中国一项多中心研究探讨了免疫抑制的HIV感染者中痘病毒肺炎的临床和影像学特征。

阅读:1

Abstract

BACKGROUND: In people living with HIV, particularly with low CD4(+) T-cell counts, monkeypox virus (Mpox) can disseminate to visceral organs, leading to severe outcomes. Mpox pneumonia is a prominent severe phenotype, but systematic reports from China are scarce. METHODS: This multicenter retrospective study analyzed 41 HIV-infected patients with Mpox (June 2022-February 2025), divided into a pneumonia group (n = 21) and a control group (n = 20). Clinical, laboratory, and thin-section chest computed tomography (CT) findings, multisystem involvement, outcomes, and the roles of immune status and antiretroviral therapy (ART) adherence were compared. RESULTS: All patients were men who have sex with men. Mpox pneumonia occurred almost exclusively in patients with CD4(+) T-cell counts <200/μL. Thin-section CT revealed multiple, randomly distributed, well-demarcated, non-enhancing nodules (2-36 mm), consistent with hematogenous necrotizing lesions. All pneumonia cases had ≥2 organ systems involved (e.g., proctitis, necrotic skin lesions, intestinal obstruction, sepsis). Compared with controls, pneumonia patients showed more frequent inflammation and organ injury markers (elevated C-reactive protein, procalcitonin, D-dimer, creatinine, and anemia). The case fatality rate was 38.1% (8/21) in the pneumonia group versus 0% in controls. Patients with consistent ART recovered, whereas all deaths occurred in those untreated or with irregular ART adherence. CONCLUSION: Mpox pneumonia in HIV-infected individuals primarily affects those with advanced immunosuppression, presenting with disseminated necrotizing pulmonary nodules, multisystem involvement, and high mortality. Consistent ART markedly improves prognosis, highlighting the need for early identification of high-risk patients and integrated management-including sustained ART and targeted Mpox treatment-to reduce severe outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。